Topic: drug reimbursement
Pfizer and Astellas’ Xtandi lost its bid to expand to the U.K. market after an English watchdog said it was ineffective in extending survival over placebo.
AstraZeneca’s Imfinzi is working to grab sales in a rival-free sector of the lung cancer market, and England’s cost watchdogs just gave it a boost.
BioMarin and NICE have been negotiating for a year, but that hasn’t helped the company secure reimbursement for its Batten disease drug.
Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
In a first, Pfizer promises reimbursement of up to 33.5% of Ibrance costs for eligible Chinese breast cancer patients.
This webinar will review PRO reimbursement strategies and how to use PRO data in the post-approval environment.
Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its next-generation cell and gene therapies.
Amgen declared the launch of migraine drug Aimovig an unqualified success, but analysts weren't quite ready to buy in to the euphoria.
AbbVie is counting on oncology med Venclexta to drive serious growth, especially as biosimilars to top seller Humira advance. But England has other plans.